✦ LIBER ✦

Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results

✍ Scribed by Palumbo, Antonio; Falco, Patrizia; Falcone, Antonietta; Benevolo, Giulia; Canepa, Letizia; Gay, Francesca; Larocca, Alessandra; Magarotto, Valeria; Gozzetti, Alessandro; Luraschi, Annalisa; Morabito, Fortunato; Nozza, Andrea; Knight, Robert D.; Zeldis, Jerome B.; Boccadoro, Mario; Petrucci, Maria Teresa

Book ID: 119936101
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 123 KB
Volume: 9
Category: Article
ISSN: 1557-9190
DOI: 10.3816/clm.2009.n.035

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

B094 Melphalan, Prednisone and Lenalidom

B094 Melphalan, Prednisone and Lenalidomide: Kinetics of Hematologic Toxicity and Time to Event Results

✍ Palumbo, A; Zeldis, JB; Boccadoro, M; Petrucci, MT; Falco, P; Gay, F; Corradini, 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 85 KB

Enoxaparin or aspirin for the prevention

Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide

✍ A. PALUMBO; C. RUS; J. B. ZELDIS; F. RODEGHIERO; M. BOCCADORO; THE ITALIAN MULTI 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Long-term Results of Response to Therapy

Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma

✍ Lacy, Martha Q.; Gertz, Morie A.; Dispenzieri, Angela; Hayman, Suzanne R.; Geyer 📂 Article 📅 2007 🏛 Mayo Clinic 🌐 English ⚖ 76 KB

Characterization of haematological param

Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial

✍ Paul Richardson; Rudolf Schlag; Nuriet Khuageva; Meletios Dimopoulos; Ofer Shpil 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Consensus guidelines for the optimal man

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

✍ A. Palumbo; F. Davies; M. Kropff; J. Bladé; M. Delforge; F. Leal da Costa; R. Ga 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 206 KB

Risk factors for, and reversibility of,

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

✍ Meletios A. Dimopoulos; Maria-Victoria Mateos; Paul G. Richardson; Rudolf Schlag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB